Cannabis Industry Update: Federal Hemp Ban Takes Effect and Banking Reform Gains Momentum
As the federal ban on intoxicating hemp products begins, a coalition of governors is pushing Congress to finally address cannabis banking reform.
Federal Hemp Restrictions Begin
As of November 12, 2026, the first phase of a federal ban on intoxicating hemp-derived cannabinoid products has officially taken effect [4, 10]. This regulatory shift targets products containing unnatural cannabinoids, such as THC-O, marking a significant change in the landscape for hemp-based retailers and manufacturers across the country [10]. Industry stakeholders are closely monitoring how these federal enforcement measures will interact with ongoing state-level litigation and regulatory adjustments [1, 4].
Governors Push for Banking Reform
Despite the shifting federal landscape, the push for cannabis banking access remains a top priority for state leadership. A coalition of 16 governors recently sent a formal letter to Congress, urging the passage of legislation that would grant marijuana businesses greater access to the banking system [1]. The governors argue that such reform is essential to protect public safety, increase tax revenues, and improve transparency within the legal market [1]. While the political composition of the incoming Congress has sparked discussions about potential legislative openings, industry experts note that banking reform has historically faced significant hurdles regardless of which party holds the majority [2].
State-Level Developments
While federal policy remains in flux, state legislatures are already preparing for the 2027 session. In Texas, lawmakers have begun pre-filing bills that range from medical cannabis expansion to full recreational legalization [1, 6]. Meanwhile, in Massachusetts, regulators are moving to modernize testing rules to ensure consistency across the industry, reflecting a broader trend of states refining their regulatory frameworks to support mature markets [8]. As we head into the weekend, the industry continues to balance these evolving policy challenges with a commitment to providing safe, regulated access for consumers and patients alike.